Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.
BACKGROUND
The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included.


RESULTS
Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with a sensitivity of 93.7 % and a specificity of 92.3 % (PPV = 93.7 % and NPV = 92.3 %), offered the best combination for predicting optimal cytoreduction. In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying platinum-sensitive patients.


CONCLUSIONS
The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal cytoreduction is promising.
Department of Breast and Gynecological Surgery, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France. a.komorek@gmail.com.|Versailles-St-Quentin-en-Yvelines University, EA 7285: Risques cliniques et sécurité en santé des femmes et en santé périnatale, Versailles, France. a.komorek@gmail.com.
Aurélie
A
Pelissier
Department of Breast and Gynecological Surgery, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France.
Aurélie
A
Roulot
Laboratory of Biological Oncology, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France.
Béatrice
B
Guéry
Department of Breast and Gynecological Surgery, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France.
Claire
C
Bonneau
Laboratory of Biological Oncology, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France.
Dominique
D
Bellet
Department of Breast and Gynecological Surgery, Centre René Huguenin, Institut Curie, 35 rue Dailly, 92210, Saint Cloud, France.|Versailles-St-Quentin-en-Yvelines University, EA 7285: Risques cliniques et sécurité en santé des femmes et en santé périnatale, Versailles, France.
Roman
R
Rouzier
Advanced ovarian cancer; CA125; HE4; Neoadjuvant chemotherapy; Optimal cytoreduction; Platinum sensitivity; Predictive value
Rev Obstet Gynecol. 2011;4(1):15-21
21629494
Gynecol Oncol. 2012 May;125(2):362-6
22333992
Int J Gynecol Cancer. 2011 Dec;21(9):1573-8
21811175
Eur J Gynaecol Oncol. 2012;33(4):382-90
23091895
Tumour Biol. 2014 Dec;35(12):12389-95
25190018
Int J Gynecol Cancer. 2011 Aug;21(6):1040-7
21738039
Gynecol Oncol. 2014 Dec;135(3):542-6
25223808
Cancer. 1950 Jan;3(1):32-5
15405679
J Ovarian Res. 2014 Jun 10;7:62
25018782
J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63
17105988
Gynecol Oncol. 2013 Mar;128(3):579-83
23220563
Acta Obstet Gynecol Scand. 2001 Jun;80(6):583-5
11380298
Int J Gynecol Cancer. 2016 Jan;26(1):43-51
26588231
N Engl J Med. 2010 Sep 2;363(10):943-53
20818904
Gynecol Oncol. 2000 May;77(2):227-31
10785469
Gynecol Oncol. 2002 Jul;86(1):57-61
12079301
Cochrane Database Syst Rev. 2016 Jan 09;(1):CD006014
26747297
Gynecol Obstet Invest. 2004;57(3):153-6
14726621
J Surg Oncol. 2010 Jan 1;101(1):13-7
20025071
Gynecol Oncol. 2013 Feb;128(2):245-51
23178313
Clin Chem. 2011 Nov;57(11):1534-44
21933899
Asian Pac J Cancer Prev. 2010;11(1):111-6
20593939
Tumour Biol. 2011 Dec;32(6):1087-95
21863264
Int J Gynecol Cancer. 2012 Jul;22(6):1000-5
22426406
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):120-4
12657110
J Clin Oncol. 2002 Mar 1;20(5):1248-59
11870167
Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80
8166218
J Gynecol Oncol. 2013 Apr;24(2):141-5
23653831
Oncol Lett. 2013 Jul;6(1):28-34
23946773